Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 28, 2024

BUY
$1.38 - $2.29 $49,391 - $81,961
35,791 New
35,791 $56,000
Q3 2022

Nov 08, 2022

SELL
$3.32 - $5.69 $118,524 - $203,133
-35,700 Reduced 49.94%
35,791 $153,000
Q3 2021

Oct 14, 2021

BUY
$7.84 - $12.53 $560,489 - $895,782
71,491 New
71,491 $573,000

Others Institutions Holding VIRX

About Viracta Therapeutics, Inc.


  • Ticker VIRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,558,200
  • Market Cap $9.39M
  • Description
  • Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...
More about VIRX
Track This Portfolio

Track Hamilton Lane Advisors LLC Portfolio

Follow Hamilton Lane Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hamilton Lane Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hamilton Lane Advisors LLC with notifications on news.